25 results on '"Lv D"'
Search Results
2. 1838P AI-based smart oncology follow-up system: Prospective application testing and enhancement of clinical efficacy
3. 1371P An anti-EpCAM x CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion in NSCLC patients: Intermediate results of a prospective multicenter phase Ib trial
4. 1255MO A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
5. 1248P Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis
6. 605O YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
7. 3MO First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial
8. 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China.
9. 677P Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China.
10. 644P Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study.
11. 1339P Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: A randomized, double-blind, multicenter phase III study
12. 1649P Anlotinib plus oral fluoropyrimidine S1 in treating patients with refractory or relapsed small cell lung cancer (SALTER TRIAL): An open-label, multicenter, single-arm, phase II trial
13. 1370TiP Befotertinib versus icotinib as first-line treatment in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer: A multicenter, randomized, open-label, controlled phase III study
14. 563P Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
15. 519P Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
16. LBA9 Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
17. LBA93 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)
18. 689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
19. 257P The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
20. 665P Real-world effectiveness and safety of first-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study).
21. 691P Mechanisms of acquired resistance to first-line (1L) osimertinib in EGFR-mutated (EGFRm) advanced NSCLC: Results from a prospective, multi-center, real-world study in China (FLOURISH study).
22. 728TiP Osimertinib with chemotherapy as first-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT).
23. 653P Baseline and 3 weeks on-treatment plasma EGFR mutation (EGFRm) dynamics in patients with EGFR mutant advanced NSCLC treated with first-line osimertinib: A prospective, multi-center, real-world analysis.
24. LBA6 PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT).
25. 57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.